Candel Therapeutics CEO urges stronger patient role to drive innovation at BioEquityEurope

Candel Therapeutics CEO urges stronger patient role to drive innovation at BioEquityEurope
Candel Therapeutics promotes patient-driven innovation

Candel Therapeutics, Inc. CEO Paul-Peter Tak joined a panel at BioEquityEurope focused on Patient Engagement Strategies.

During the discussion, Tak outlined how incorporating the patient perspective can shape the trajectory of innovation in drug discovery and development. The session emphasized the increasing importance of prioritizing patient needs to inform research directions and improve healthcare outcomes, especially for companies seeking to advance new therapies in the biotech sector.

Candel Therapeutics is preparing to present new phase 3 trial follow-up data for its CAN-2409 immunotherapy in prostate cancer at AUA2026. The company has also advanced viral immunotherapies targeting prostate, lung, and brain cancers in its latest research drive, according to a recent update here. These initiatives highlight the firm's ongoing focus on clinical development in oncology.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.